High Potency Active Pharmaceutical Ingredients; Effective at Much Smaller Dosage Levels than Traditional APIs
High potency active pharmaceutical ingredients (HPAPIs) are compounds that elicit a biological response at a very low dose/concentrations, such as a daily therapeutic dose of <10 mg or an occupational exposure limit (OEL) of < 10 μg/m3 at an eight-hour time-weighted average. High potent drugs represent a growing proportion of medicines, including therapies in development and those commercially available. The active ingredient in a pharmaceutical drug is called an API. An example of an API is the acetaminophen contained in a pain relief tablet.
The
active ingredient in a biological drug is called a bulk process intermediate
(BPI). Demand for High
Potency Active Pharmaceutical Ingredients is increasing at a rapid pace due
to its ability to target diseased cells more precisely and selectively than
other APIs. A highly potent drug (bisoprolol, bumetanide, risperidone,
alprazolam, and fentanyl) evokes a given response at low concentrations,
whereas a drug of lower potency (metoprolol, furosemide, ziprasidone, diazepam,
and meperidine) evokes the same response only at higher concentrations.
High
potency active pharmaceutical ingredients are compounds that elicit a
biological response at a very low dose. However, any type of compound can be
highly potent if it causes a response at a low dose. A substance with high
potency will have a big effect on the body, and something with low potency will
have a smaller one. Many of these drugs have accelerated timelines for approval
& commercial development. HPAPI services by Piramal Pharma offer
manufacturing of HPAPIs through its FDA-approved cGMP state-of-the-art facility
in the U.S.
Potency
is an expression of a drug's activity in terms of the concentration or amount
of a drug needed to produce the defined effect, while clinical efficacy judges a drug's therapeutic effectiveness in humans. High potency active pharmaceutical
ingredients (HPAPI) represent an increasingly significant share of the
pharmaceutical drug pipeline.
Comments
Post a Comment